Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test.

Elder CJ, Vilela R, Johnson TN, Taylor RN, Kemp EH, Keevil BG, Cross AS, Ross RJ, Wright NP

The Journal of clinical endocrinology and metabolism1 Aug 2020Cited by 9 (Europe PMC)

PMID32593173DOI10.1210/clinem/dgaa323PepBankPUB-32593173

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

01HumanNot a test of Cosyntropin aloneRandomized controlled trialActivity measurement
In healthy participants, adding chitosan to nasal tetracosactide increased peak cortisol response (P = 0.01).
In plain wordsIn healthy participants, nasal tetracosactide with chitosan increased peak cortisol more than tetracosactide without chitosan.
Peptide
Cosyntropin
Outcome
IncreasePeak cortisol with chitosan formulation
Study
n: not reported in source
Comparator
Tetracosactide without chitosan
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Source sentences
Summary
The addition of chitosan to tetracosactide and dose escalation increased peak cortisol response (P = 0.01 and 0.001, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317301
02HumanNot a test of Cosyntropin aloneRandomized controlled trialActivity measurement
In healthy participants, nasal tetracosactide dose escalation increased peak cortisol response (P = 0.001).
In plain wordsIn healthy participants, higher nasal tetracosactide doses increased peak cortisol more than lower doses.
Peptide
Cosyntropin
Outcome
IncreasePeak cortisol with dose escalation
Study
n: not reported in source
Comparator
Lower nasal tetracosactide doses
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Source sentences
Summary
The addition of chitosan to tetracosactide and dose escalation increased peak cortisol response (P = 0.01 and 0.001, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317302
03HumanNot a test of Cosyntropin aloneRandomized controlled trialActivity measurement
In healthy participants, plasma cortisol at 60 minutes did not significantly differ between 500 µg nasal Nasacthin003 and 250 µg intravenous Synacthen.
In plain wordsIn healthy participants, nasal tetracosactide and intravenous Synacthen produced no significant difference in cortisol at 60 minutes.
Peptide
Cosyntropin
Outcome
No significant changePlasma cortisol at 60 minutes
Study
n: not reported in source
Comparator
250 µg intravenous Synacthen
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Source sentences
Summary
There was no significant difference in plasma cortisol at 60 minutes between 500 µg Nasacthin003 and 250 µg IV Synacthen (P = 0.17).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317304
04HumanNot a test of Cosyntropin aloneNon-randomized trialPharmacokinetics
In healthy children, nasal tetracosactide Nasacthin003 had bioavailability of 14.3%.
In plain wordsIn healthy children, nasal tetracosactide had bioavailability of 14.3%.
Peptide
Cosyntropin
Outcome
Not applicableNasacthin003 bioavailability
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Bioavailability
14.3%
Nasacthin003
Source sentences
Summary
The bioavailability of Nasacthin003 was 14.3%.
3 context sentences(design, population, supporting numbers)
Summary · context
Additionally, pharmacokinetic analysis was undertaken using our chosen formulation, 500 µg tetracosactide with mucoadhesive chitosan, Nasacthin003, in our pediatric study.
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317303
05HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy participants, the intravenous Synacthen cortisol repeatability coefficient at 60 minutes was 105 nmol/L.
In plain wordsIn healthy participants, intravenous Synacthen testing had a cortisol repeatability coefficient of 105 nmol/L.
Peptide
Cosyntropin
Outcome
Not applicableRepeatability of intravenous Synacthen plasma cortisol
Study
n: not reported in source
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Measurements
Repeatability coefficient
105 nmol/L
IV Synacthen at 60 minutes
Source sentences
Summary
The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317305
06HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy participants, the salivary cortisol repeatability coefficient at 60 minutes was 10.3 nmol/L.
In plain wordsIn healthy participants, salivary cortisol testing had a repeatability coefficient of 10.3 nmol/L.
Peptide
Cosyntropin
Outcome
Not applicableSalivary cortisol repeatability
Study
n: not reported in source
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Measurements
Repeatability coefficient
10.3 nmol/L
Salivary cortisol at 60 minutes
Source sentences
Summary
The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317306
07HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy participants, the salivary cortisone repeatability coefficient at 60 minutes was 21.1 nmol/L.
In plain wordsIn healthy participants, salivary cortisone testing had a repeatability coefficient of 21.1 nmol/L.
Peptide
Cosyntropin
Outcome
Not applicableSalivary cortisone repeatability
Study
n: not reported in source
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Measurements
Repeatability coefficient
21.1 nmol/L
Salivary cortisone at 60 minutes
Source sentences
Summary
The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317307
08HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
With nasal tetracosactide testing, glucocorticoid responses in healthy children were indistinguishable from those in adults.
In plain wordsWith nasal tetracosactide testing, healthy children and adults had indistinguishable glucocorticoid responses.
Peptide
Cosyntropin
Outcome
Not applicableGlucocorticoid response by age group
Study
n: not reported in source
Comparator
Healthy adults
Outcome group
Adrenal Diagnostic Testing · Endocrine and hormones
Source sentences
Summary
The glucocorticoid response in children was indistinguishable from that of adults.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted 5 studies: 4 open-label, sequence-randomized, crossover, pharmacodynamic studies testing 6 doses/formulations and a repeatability study.
Summary · context
A total of 36 healthy adult males and 24 healthy children.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-3259317308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.